DDX60L

Across TCGA pan-cancer cohorts, DDX60L mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of DDX60L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DDX60L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types DDX60L is over-expressed in tumor, although a few such as LSCC and COAD show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where DDX60L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DDX60L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.397	<.001	9	view →
HNSC	All	IV	+0.622	<.001	8	view →
PDAC	All	II,III,IV	+0.412	<.001	7	view →
LSCC	All	All	−0.205	<.001	6	view →
COAD	All	II,III,IV	−0.249	.013	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

DDX60L–CCRCC

Open the CCRCC breakdown →